South & Central America Cerebrospinal Fluid Management Market

The South & Central America cerebrospinal fluid management market was valued at US$ 92.52 million in 2022 and is expected to reach US$ 123.89 million by 2030; it is estimated to grow at a CAGR of 3.7% from 2022 to 2030.

Increasing Focus on CSF Management in Neurological Disease Treatments Fuels the South & Central America Cerebrospinal Fluid Management Market

CSF parameters are extensively evaluated as biomarkers of neurological disorders in adult patients. Circulating microRNAs in CSF are a promising class of biomarkers for the diagnosis of various neurological diseases. Neurological disorders such as Parkinson’s Disease (PD), Alzheimer’s Disease (AD), epilepsy, and seizures often lead to altered CSF parameters. According to an article published in Nature, 76 CSF proteins were found to be structurally altered in patients that were diagnosed with PD when compared to normal individuals. The study also suggests that these CSF proteins can be used as biomarkers for the diagnosis or treatment of the disease. PD is a neurodegenerative disease associated with loss of cognitive impairment and motor function. According to the World Health Organization (WHO) report published in 2022, the prevalence of PD has doubled in the last 25 years, affecting ~1% of the global population aged more than 60 years. Similarly, a few of the CSF parameters such as protein and lactate levels are altered in patients suffering from seizure or status epilepticus. Therefore, various R&D activities are going on for using CSF parameters in the treatment of seizures or epilepsy. Further, despite the availability of various CSF assays for the detection of Alzheimer’s disease using CSF in the market, there are unmet needs for biomarkers for detection and treatment purposes. As the detection of cases of Alzheimer’s disease and PD increases, there is increase in demand for CSF management devices as the cases of CSF leaks may increases. Therefore, a rise in the prevalence of neurological disorders is fueling the research and development activities for the use of CSF management products in the treatment of these disorders.

South & Central America Cerebrospinal Fluid Management Market Overview

The cerebrospinal fluid management market in South & Central America is segmented into Brazil, Argentina, and the Rest of South & Central America. The growth of the market in the region is expected due to several opportunities offered by increasing import of medical devices, growing developments of healthcare systems that demand advanced medical technologies and growing geriatric population.

South & Central America Cerebrospinal Fluid Management Market Revenue and Forecast to 2030 (US$ Mn)

South & Central America Cerebrospinal Fluid Management Market Segmentation 

The South & Central America cerebrospinal fluid management market is segmented into product, end user and country.

Based on product, the South & Central America cerebrospinal fluid management market is bifurcated into CSF shunts and CSF drainage systems. The CSF shunts segment held a larger market share in 2022.

Based on end user, the South & Central America cerebrospinal fluid management market is segmented into hospitals, clinics, ambulatory surgical centers, and others. The hospitals segment held the largest market share in 2022.

Based on country, the South & Central America cerebrospinal fluid management market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America cerebrospinal fluid management market share in 2022.

B. Braun SE, Integra LifeSciences Holdings Corp, Medtronic Plc, and Spiegelberg GmbH & Co KG are some of the leading companies operating in the South & Central America cerebrospinal fluid management market.